World's first postbiotics.
HYA™ is the world's first postbiotic component that has been confirmed to have beneficial effects on maintaining normal body metabolism, including stimulating the secretion of the intestinal hormone GLP-1, improving insulin resistance, suppressing increases in postprandial blood glucose levels, improving obesity, and improving gut microbiome.
HYA™ is a postbiotic component that is produced by the metabolism of linoleic acid by lactic acid bacteria and other gut microbes and plays a major role in maintaining the host's biological homeostasis.
HYA™ promotes the secretion of GLP-1 via the lipid receptor GPR40/120, suppressing the increase in postprandial blood glucose levels and improving insulin resistance. It has also been shown to have an anti-obesity effect by stimulating the secretion of PYY and improves a range of metabolic functions.
HYA™ has a high affinity for the lipid receptor GPR40/120, which is expressed in various tissues,
including the intestinal tract.
※■▲◆● Doxycycline-treatedPrepared based on the procedures reported in "Nature Communications. 10,4007 (2019)".
HYA™ exhibits a wide range of physiological activities that have been elucidated through joint research with universities and research institutes.
Here we introduce some of our academic partners who have made the practical realization of Postbiotics and HYA™.
Clinical trials have confirmed that taking HYA™ immediately before a meal inhibits the rapid rise in blood glucose levels after a meal.
| Group | Fasting | 30 mins | 60 mins | 90 minutes | 120 min | AUC | Cmax |
| Placebo | 98.6±6.6 | 151.3±17.5a | 146.2±31.2a | 136.1±27.5 | 131.0±20.8 | 274.2±39.2 | 159.0±23.8 |
| 50%HYA (2,000 mg) | 99.0±6.7 | 127.8±21.9b | 134.9±21.9b | 140.2±27.3 | 132.7±23.3 | 259.4±29.0** | 151.4±21.0** |
| 50%HYA (4,000 mg) | 98.3±6.9 | 117.7±13.8c | 131.9±22.4b | 138.3±24.9 | 134.0±25.9 | 252.1±24.8** | 150.2±19.7** |
| Means ± SD （N = 60） Different letters represent significant differences between groups ; P<0.01 | |||||||
| Group | Fasting | 30 mins | 60 mins | 90 minutes | 120 min | AUC | Cmax |
| Placebo | 100.3±9.9 | 161.6±16.5 | 163.3±27.4 | 144.4±27.5 | 134.2±24.1 | 293.3±38.0 | 171.2±22.2 |
| 50%HYA (600 mg) | 98.7±7.7* | 144.9±22.0** | 158.7±26.9 | 148.2±24.1 | 134.8±24.4 | 284.3±35.8** | 166.7±22.1* |
| Means ± SD （N = 60）*P<0.05、** P<0.01（Versus to placebo） | |||||||
Test conditions
| Name of study | Confirmation study of the effect of HYA-containing supplement intake on postprandial blood glucose AUC values and postprandial blood glucose levels in subjects with elevated postprandial blood glucose levels (a randomized, placebo-controlled, double-blind, crossover study) | ||
|---|---|---|---|
| Objectives | To study the effect of HYA-containing supplement on postprandial blood glucose in men and women aged 20-69 years. | ||
| Investigational product |
Investigational product |
HYA-containing supplement |
HYA 50%、LA20%、OA6%、other24% |
| Related components |
10-hydroxy-cis-12-octadecenoic acid (HYA;C18H34O3) | ||
| Form, packaging |
Capsules, aluminum sachets | ||
| Intake dose | Dose-finding study 1 sachet (200 capsules) once daily 0 mg HYA (placebo) 1,000 mg HYA (2,000 mg of 50% pure HYA) 2,000 mg HYA (4,000 mg of 50% pure HYA) |
Efficacy confirmation study One packet (30 capsules) once daily 0 mg HYA (placebo) 300 mg HYA (600 mg of 50% pure HYA) |
|
| Subjects | Number of subjects |
60 subjects (20 x 3 groups) Placebo-controlled crossover | 60 subjects (30 subjects x 2 groups) Placebo-controlled crossover |
| Inclusion criteria |
Subjects with a blood glucose level of (140-199 mg/dL) 30 minutes after a meal at the time of the pre-test. | ||
| Methods | Endpoint | Area under the concentration-time curve for blood glucose level (AUC) and peak postprandial blood glucose level (Cmax) | |
| Period of implementation |
July 2016~January 2017 | April 2017~February 2018 | |
A single dose of HYA promotes GLP-1 secretion and increases insulin levels and it has been confirmed in a study using mice that HYA suppresses the increase in postprandial blood glucose levels.
**P < 0.01; *P < 0.05 vs. control (Tukey–Kramer test). ##P <0.01; #P < 0.05 vs. HYA (Tukey–Kramer test).
Test conditions
| Evaluation system | Mouse (C57BL/6L) |
|---|---|
| Grouping | HYA group (1,000 mg/kg) LA group (1,000 mg/kg) Control group |
| Administration method | Single oral administration |
Clinical studies have confirmed that continuous intake of HYA™ reduces the area of abdominal visceral fat.
| Group | Baseline | 4weeks | 8weeks | 12weeks |
| Placebo | 129.1±49.0 | 129.5±49.9 | 129.0±51.0 | 128.4±46.0 |
| 50%HYA (1,800 mg) | 127.6±45.5 | 121.7±43.4 | 1121.1±43.5 | 117.1±43.6* |
| Means ± SD （N = 56）*P<0.05（Versus to placebo） | ||||
Test conditions
| Name of study | Effect of test food intake on visceral fat in healthy subjects: A randomized, double-blind, parallel-group, placebo-controlled study | |
|---|---|---|
| Objectives | To verify the effect on visceral fat area when healthy subjects continuously ingested test food for 12 weeks. | |
| Product studied | Product studied | HYA-containing supplement |
| Related components | 10-hydroxy-cis-12-octadecenoic acid (HYA; C18H34O3) | |
| Form | Soft capsule | |
| Intake dose | 9 capsules（Take 3 capsules 3 times a day just before meals） ・0 mg HYA (placebo) ・9000 mg HYA (1,800 mg of 50% pure HYA) |
|
| Subjects | Number of subjects | 56 people (28 x 2 groups) Randomized, double-blind, parallel-group comparative study |
| Inclusion criteria | Those with a BMI of between 23 to 30 | |
| Methodology | Items evaluated | Abdominal visceral fat area (cm2) after 12 weeks |
| Period of implementation | March 2021~December 2021 | |
Oral administration of HYA™ to mice fed a high-fat diet has been shown to suppress weight gain by promoting the secretion of the intestinal hormones GLP-1 and PYY and suppressing appetite.
**P < 0.01; *P < 0.05 vs. control (Tukey–Kramer test). ##P < 0.01; #P < 0.05 vs. HYA (Tukey–Kramer test).
Test conditions
| Evaluation system | High-fat diet-loaded obese mouse model (C57BL/6J) |
|---|---|
| Grouping | HYA group (1% HYA in high-fat diet) LA group (high-fat diet with 1% LA) Control group (high-fat diet only) |
| Administration method | Long-term oral administration (12 weeks) |
Oral administration of HYA™ to mice fed on a high-fat diet has been shown to increase Lactobacillus lactobacillus and promote the production of functional lipid metabolites in the gut, such as KetoA and αHYA.
Test conditions
| Evaluation system | High-fat diet-loaded obese mouse model (C57BL/6J) |
|---|---|
| Grouping | HYA group (high-fat diet containing 1% HYA) LA group (high-fat diet with 1% LA) Control group (high-fat diet only) |
| Administration method | Long-term oral administration (12weeks) |
HYA™ has been shown to inhibit the production of inflammatory cytokines via GPR40, restore tight junction factors (intestinal barrier) and relieve acute intestinal inflammatory symptoms.
n=6 **P < 0.01 and * P < 0.05 vs untreated, ## P < 0.01 vs ( - ), $$ P < 0.01 vs HYA
Test conditions
| Evaluation system | DSS-induced intestinal inflammation model mice |
|---|---|
| 群分け | Un-treated group DSS group (DSS only) HYA group (DSS + HYA 30 µg/day) HYB group (DSS + HYB 30 µg/day) |
| Administration method | Oral administration (10 days) |
Ingestion of HYA™ has been shown to alleviate periodontal symptoms and inhibit the expression of inflammatory substances in periodontal tissue in mice with periodontitis.
ABC: alveolar bone apex CEJ: first molar cemento-enamel border
P < 0.01 vs unligated as indicated
Test conditions
| Evaluation system | Mouse model of P. gingivalis-induced periodontitis |
|---|---|
| Grouping | Un-ligated group Un-ligated+HYA group (water containing 50 mM HYA) P. gingivalis group P. gingivalis+HYA group (water containing 50 mM HYA) |
| Administration method | Oral administration (14days) |
In experiments using human liver-derived cells, HYA™ has been shown to inhibit the accumulation of triglycerides in the cells.
Test conditions
| Fatty acids tested | HYA, LA (linoleic acid), EPA (eicosapentaenoic acid) |
|---|---|
| Experimental method | Human liver-derived cells (HepG2) were cultured with each fatty acid (60 µM) and the amount of accumulated triglycerides measured |
HYA™ has been shown to inhibit the growth of H. pylori by inhibiting the Helicobacter-specific menaquinone synthesis pathway.
Test conditions
| Test strains | Helicobacter pylori SS1: mouse isolate Helicobacter pylori TN2GF4: clinical isolate |
|---|---|
| Experimental method | Ingestion (10^5-6 CFU/mL) of two B. pylori strains into liquid medium (BH + 5% FBS) containing HYA (20µM) or linoleic acid (LA, 20µM) ± MK-4 (225µM), shaking for 24 hours, culture medium is then applied to Helicobacter agar medium to determine number of H. pylori. |
Administration of HYA™ has been shown to improve insulin resistance (difficulty in insulin response) caused by obesity and to suppress increases in blood glucose levels.
**P < 0.01; *P < 0.05 vs. control (Tukey–Kramer test). ##P < 0.01; #P < 0.05 vs. HYA (Tukey–Kramer test).
Test conditions
| Evaluation system | High-fat diet-loaded obese mouse model (C57BL/6J) |
|---|---|
| Grouping | HYA group (high-fat diet containing 1% HYA) LA administration group (high-fat diet with 1% LA) Control group (high-fat diet only) |
| Administration method | Long-term oral administration (12weeks) |
